Fasting plasma insulin modulates lipid levels and particle sizes in 2- to 3-year-old children

Steven Shea1, Eve Aymong, Patricia Zybert

  • 1Division of General Medicine, Columbia University College of Physicians & Surgeons, New York, New York 10032, USA. ss35@columbia.edu

Obesity Research
|June 14, 2003
PubMed

Insights

In healthy young children, higher fasting insulin levels are linked to unhealthy lipid profiles, including elevated triglycerides and smaller high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Health
  • Cardiovascular Risk Factors

Background:

  • Obesity and hyperinsulinemia are known risk factors for dyslipidemia in adults and older children.
  • However, the relationship between insulin levels and lipid profiles in very young children remains understudied.

Purpose of the Study:

  • To investigate the association between fasting insulin levels and lipid profiles, including particle size, in healthy 2- and 3-year-old children.

Main Methods:

  • Analysis of data from 491 healthy Hispanic children aged 2-3 years.
  • Measurements included Body Mass Index (BMI), ponderal index, skinfold thickness, and waist circumference.
  • Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle sizes were determined using nuclear magnetic resonance.

Main Results:

  • Fasting insulin levels positively correlated with triglyceride levels in both boys and girls.
  • Fasting insulin levels were inversely correlated with HDL-cholesterol levels in boys.
  • Higher fasting insulin levels were associated with smaller HDL and LDL particle sizes in both sexes, even after multivariate adjustment.

Conclusions:

  • Fasting insulin levels are associated with dyslipidemia in healthy young children.
  • These findings highlight potential early markers for metabolic disturbances in pediatric populations.
Abstract

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.